FDA panel votes 15-1-1 that Abbott's (ABT) Humira benefit is meaningful
Tweet Send to a FriendGet Alerts ABT Hot Sheet
Up)
Trade ABT Now!
FDA panel votes 15-1-1 that Abbott's (NYSE: ABT) Humira benefit is meaningful. The panel also said Humira has benefit in UC after 8 weeks.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Absolute Software Featuring Product Portfolio at Gartner IT Infrastructure & Operations Management Summit
- Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
- Abbott (ABT) Approves New $3B Buyback Plan
Create E-mail Alert Related Categories
FDA, General News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
